

## Association Between Galectin-3 and Oxidative Stress Parameters with Coronary Artery Disease in Tunisian Population

Trimèche-Othmani T<sup>1</sup>, Vodovar N<sup>4</sup>, Callebert J<sup>2</sup>, Maatouk F<sup>3</sup>, Launay JM<sup>2</sup>, Mebazaa A<sup>4,5</sup> and Kenani A<sup>1\*</sup>

<sup>1</sup>UR12ES08- Faculté de Médecine de Monastir- Université de Monastir, Tunisia

<sup>2</sup>Department of Biochemistry, Lariboisière Hospital, Paris, France

<sup>3</sup>Department of Cardiology, Fattouma Bourguiba Hospital, Monastir, Tunisia

<sup>4</sup>Inserm UMR-S 942, Paris, France

<sup>5</sup>Department of Anesthesiology and Intensive Care, Lariboisière Hospital, Paris, France

### \*Corresponding author:

Abderraouf Kenani,  
UR12ES08- Faculté de Médecine de Monastir-  
Université de Monastir, Tunisia,  
E-mail: raouf.kenani@fmm.rnu.tn

Received: 02 Sep 2022

Accepted: 15 Sep 2022

Published: 20 Sep 2022

J Short Name: ACMCR

### Copyright:

©2022 Kenani A. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

### Citation:

Kenani A, Association Between Galectin-3 and Oxidative Stress Parameters with Coronary Artery Disease in Tunisian Population. *Ann Clin Med Case Rep.* 2022; V9(14): 1-7

### Keywords:

Galectin-3; Coronary artery disease; Coronary severity score; Score Gensini; Oxidative stress

## 1. Abstract

**1.1. Background:** Galectin-3 (Gal-3), as a mediator of inflammation and fibrosis, has been reported to be a biomarker of severity in coronary artery disease (CAD). The study aimed to assess the relationships between coronary artery disease (CAD) and risk factors, including parameters of oxidative stress in Tunisian patients CAD.

**1.2. Methods:** The study enrolled 257 patients affected by CAD. Serum Gal-3 was measured using ELISA and stress oxidative parameters was assayed in erythrocytes.

**1.3. Results and conclusions:** Unstable patients had a higher plasma Galectin-3 level compared to the stable subjects. We hypothesize that Gal-3 could be a useful biomarker of atherosclerotic plaque and in particular of its destabilization. We conclude that oxidative stress could be an important supplemental parameter to predict CAD.

**1.4. Aims:** The goal of this study was to examine the relationships between coronary artery disease (CAD) and risk factors, including oxidative stress parameters and galectin-3 as an inflammation marker, in Tunisian patients with stable and unstable CAD.

## 2. Introduction

Coronary artery disease (CAD), macrovascular and microvascular complications are major causes of morbidity and mortality. Atherosclerosis is an inflammatory process, which involves in

the development of CAD (Hansson GK,2005; Hansson GK and al,2006, Galkina E and al,2009, Moore ,2011). Another pathway in the pathogenesis of atherosclerosis, associated with inflammation processus, is vascular fibrosis (Katsuda S,2003; Lan T.H. and al,2013).

Many reports have also suggested a link between biomarkers and CHD. Of these biomarkers, Galectin-3 is a  $\beta$ -galactoside binding lectin playing an important regulatory role in inflammation, immunity, and fibrosis (Yang RY 2008). Galectin-3 is expressed in leucocytes, mast cells and various organ tissues (Hughes RC,1997; Kim H and al, 2007) and secreted by activated macrophages. It directly induces transformation of reactive oxygen species, fibroblasts, proliferation, secretion of matrix metalloproteinases and tissue inhibitors of metalloproteinases and deposition of type I collagen in extracellular matrix, which results in adverse matrix remodeling (Lin et al, 2009).

Many studies have implicated Gal-3 in a atherogenesis and the progression of heart failure, Gal-3 was shown to have predictive value in several heart failure cohorts (de Boer et al, 2011; Felker GM, 2012). Another case control study showed that Gal-3 is a predictive marker for coronary vascular disease and might be a useful biomarker of CAD (Falcome C,2011; Grandin EW,2012)

The known traditional risk factors for CAD are smoking, obesity, hypertension, a family history of CAD, diabetes mellitus, and

hyperlipidemia. In addition to the traditional CAD risk factors, enhanced oxidative stress is a novel risk factor of CAD. Increased oxidative stress is associated with the pathogenesis of CAD (C. Antoniadis, D, 2003; R. Stocker and J, 2004). Clinical trials have revealed that oxidative stress may increase free oxygen reactive species (ROS) formation and reduce antioxidant defenses. However, oxidative stress plays an important role in the development of many pathologies (Ahsan H and al,2003; okayama Y, 2005). Malondialdehyde (MDA), the end product of lipid peroxidation, is a good marker of free radical-mediated damage and oxidative stress (Del Rio D and al, 2005). Antioxidant enzymes such as glutathione peroxidase (GPx) and superoxide dismutase (SOD) protect cells against oxidative stress (Michiels C and al,1994).

We hypothesize that Gal-3, as a biomarker linking inflammation and fibrosis, could provide useful information for the prediction of CAD.

The purpose of the present study was to verify the hypothesis that an elevated Gal-3 level is a useful biomarker in CAD and to explore antioxidant status by determining the SOD, GPx and MDA activity among coronary artery disease patients.

### 3. Materiel and Methods

#### 3.1. Population

The studied population (N = 361) consisted of 193 patients with stable coronary artery disease (SCAD), 64 patients with instable coronary artery disease (ISCAD) and 104 CAD-free control subjects recruited from the health professional department while undergoing routine check-up. Informed consent was obtained from all of the participants, and the study was approved by the local ethics committee.

The patients with CAD were included when presenting at least 50% stenosis in at least one of the major coronary arteries. Patients who suffered from inflammatory disease, heart failure, renal disease, rheumatoid arthritis or cancer were excluded. Selective coronary angiography was performed for all patients enrolled in this study. Cardiologists evaluated all of the coronary angiograms; the coronary angiogram established the lesion location and percentage of luminal stenosis among all coronary artery lesions. CAD defined as the presence of stenosis of at least 50% of the vessel diameter in any of the main coronary arteries, according to the American College of Cardiology/American Heart Association (ACC/AHA) lesion classification (Ryan TJ 1988).

#### 3.2. Measurement of plasma Gal-3 and stress oxidative parameters

Plasma samples were assayed for Galectine-3 by using an enzyme-linked immunosorbent assay (BG Medecine, Waltham, MA), according to the manufacturer's instructions. Superoxide dismutase, glutathione peroxydase and malondialdehyde were assayed in erythrocytes by according methods Beyer and Fri-

dovich(1987), Flohé and Gunzler (1984) and Yoshioka and al, (1979) respectively.

Other blood parameters were measured with standard hospital equipment.

#### 3.3. Coronary angiography and assessment of coronary atherosclerosis severity

The Gensini scoring system used to identify the severity of CAD (Gensini GG, 1983). This method classifies and scores the degree and extent of the stenosis of the coronary arteries. This system scores 1 point for 1% to 25% stenosis, 2 points for 26% to 50%, 4 points for 51% to 75%, 8 points for 76% to 90%, 16 points for 91% to 99% stenosis, and 32 points for total occlusion. The score is then multiplied by a factor representing the importance of the lesion's location in the coronary arterial system. For the location, scores are multiplied by 5 for a left main lesion; 2.5 for the proximal left anterior descending (LAD) or left circumflex (LCX) artery; 1.5 for the mid-segment LAD and LCX; 1 for the distal segment of the LAD and LCX, first diagonal branch, first obtuse marginal branch, right coronary artery, posterior descending artery, and intermediate artery; and 0.5 for the second diagonal and second obtuse marginal branches. According to their coronary angiograms, the patients with CAD were divided in two groups, patients with mild atherosclerosis (n=96; gensini score <20 points) and severe atherosclerosis (n=156; gensini score  $\geq$  20 points)).

#### 3.4. Follow-up

The patients were contacted by telephone every 2 months. The primary endpoint was a composite of all-cause mortality, restenosis and rehospitalization due to CHD during 12-month follow-up.

### 4. Statistics

Continuous variables are expressed as median and interquartile range. Categorical variables were given as percentages. The normality of distribution for continuous variables was confirmed with the kolmogorov-Smirnov test. According to the distribution pattern of the continuous variables, the independent-sample t-test or the Mann-Whitney U test was used for continuous variables, and the chi-square test was used for categorical variables. One-way analysis of variance (ANOVA) or kruskal-Wallis test was used to compare 3 groups.

Correlations were assessed using either Pearson's correlation test or Spearman's rank test according to the distribution pattern of the variable.

Independent associations between Gensini score and independent variables were assessed by backward stepwise multiple linear regression analysis by including all parameters showing p value of less than 0.1 on univariate analysis.

Receiver operating characteristic (ROC) curve analyses were performed to derive the optimal cut-off value of galectin-3 with the highest sensitivity and specificity associated with CAD.

## 5. Results

### 5.1. Baseline Characteristics

The 361 subjects were divided into groups: the controls subjects are 104 healthy volunteers (age mean 50±11 years) and 257 consecutive patients (age mean 61±11 years) with angiographically documented CVD enrolled from the cardiovascular department of University Hospital Fattouma Bourguiba of Monastir, Tunisia. The clinical characteristic, including comorbidities and risk factors, are summarized in table I. The CHD population is grouped according to the stable and unstable CAD. As expected, the CHD population had a higher percentage of diabetes, hypertensive, hyperlipidemic and smokers' patients. In contrast, only diabetes mellitus was significantly higher in the stable CAD population. However, there are differences in medical treatment between the stable and unstable CAD, although the frequency of antidiabetes, insulin, calcium antagonist therapy exhibited a tendency to be higher in the stable CAD population. The capillary glycemia, HDL cholesterol (HDL-C), total cholesterol, triglycerides, urea, sodium, creatinine, ASAT and ALAT were significantly higher in CHD patients compared to the control population, but only LDL-C was significantly

higher in unstable CAD. In contrast, the BMI, LDL-C, potassium and hemoglobin 1Ac did not differ significantly between controls and HD patients (Table 1).

### 5.2. Plasma Gal-3

By ELISA determined Galectin-3 in the plasma of controls and CHD patients, which have been divided into stable and unstable CAD (table 1). The median concentration of Gal-3 in the plasma was 14,46 [5,28- 72,85]ng/ml. Gal-3 was higher in CHD patients vs controls ( $p<0,001$ ) and in unstable CAD vs stable CAD patients ( $p<0,001$ ). By contrast, we did not find any difference in the level of Gal-3 according to our number of vessel stenosis between any of four CAD groups.

Systemic Gal-3 showed a positive correlation with HDL-cholesterol, Triglyceride, and Urea but did not correlate with BMI, LDL-cholesterol, and SOD activity (Table 4).

Of note, there was a negative correlation between the plasma levels of galectin-3 and MDA activity ( $r=-0.203$ ;  $p=0.02$ ) (Figure 1A), but there was a moderate positive correlation between galectin-3 and GPx ( $r=0.218$ ;  $p=0.01$ ) (Figure 1B).

**Table 1:** baseline clinical characteristics and risk factors in the patients with CHD, sable CAD and unsable CAD

|  | Control group n=104 | CHD n=257          | CAD satble n=193 | CAD unstable n=64 | p1      | p 2     |
|--|---------------------|--------------------|------------------|-------------------|---------|---------|
| <i>Gender (male)</i>                   | 45(43,3)            | 117(66,5)          | 128 (66,3)       | 43 (67,2)         | <0,001  | 0,89    |
| <i>Age (year)</i>                      | 49,95±11,03         | 61,49±10,67        | 62,45±10,64      | 58,58±10,22       | <0,001* | 0,011*  |
| <i>BMI (kg/m<sup>2</sup>)</i>          | 27,45±4,41          | 27,95±4,43         | 28,11±4,54       | 27,48±4,08        | 0,327   | 0,326   |
| <i>history of CAD (%)</i>              | 0(0)                | 135(52,5)          | 107 (55,4)       | 28 (43,8)         | -       | 0,105   |
| <b>Risk factors</b>                    |                     |                    |                  |                   |         |         |
| <i>Hypertension (%)</i>                | 1(1)                | 145(56,4)          | 104 (53,9)       | 41 (64,1)         | <0,001* | 0,155   |
| <i>Diabetes mellitus (%)</i>           | 3(2,9)              | 134(52,1)          | 115 (59,6)       | 19 (29,7)         | <0,001* | <0,001* |
| <i>Hyperlipidemic (%)</i>              | 0(0)                | 63(24,5)           | 43 (22,3)        | 20 (31,3)         | <0,001* | 0,148   |
| <i>Obesity (%)</i>                     | 29(27,9)            | 92(35,8)           | 73 (37,8)        | 19 (29,7)         | 0,149   | 0,239   |
| <i>Smokers (%)</i>                     | 6(5,8)              | 136(52,9)          | 107 (55,4)       | 29 (45,3)         | <0,001* | 0,194   |
| <i>IDM (%)</i>                         | 0(0)                | 55(21,4)           | 31 (16,1)        | 24 (37,5)         | <0,001* | 0,001*  |
| <i>Coronary revascularisation (%)</i>  | 0(0)                | 32(12,5)           | 26 (13,5)        | 6 (9,4)           | <0,001* | 0,383   |
| <i>Mortality</i>                       | 0(0)                | 12(4,7)            | -                | -                 | -       | -       |
| <i>restenosis</i>                      | 0(0)                | 13(5,1)            | -                | -                 | -       | -       |
| <i>Re-hospitalization</i>              | 0(0)                | 45(17,5)           | -                | -                 | -       | -       |
| <b>Laboratory data</b>                 |                     |                    |                  |                   |         |         |
| <i>Capillary glycemia (mmol/l)</i>     | 4,95[2,1-16,84]     | 8,05[2,91-35,3]    | 7,76[2,91-35,3]  | 7,42[3,72-20,9]   | <0,001* | 0,711   |
| <i>LDL-c (mmol/l)</i>                  | 2,4[0,57-4,53]      | 2,8[0,41-6,26]     | 2,74[0,41-6,26]  | 3,14[1,98-4,86]   | 0,135   | <0,001* |
| <i>HDL-c (mmol/l)</i>                  | 1,15[0,64-2,32]     | 1,05[0,27-4,27]    | 1,04[0,27-4,27]  | 1,02[0,94-1,32]   | 0,008*  | 0,232   |
| <i>Total Cholesterol (mmol/l)</i>      | 4,16±0,8            | 4,8±1,15           | 4,76±1,12        | 5,07±1,28         | <0,001* | 0,15    |
| <i>Triglycerides (mmol/l)</i>          | 1,14[0,47-3,49]     | 1,59[0,2-8,8]      | 1,59[0,2-8,8]    | 1,28[0,96-1,65]   | <0,001* | 0,339   |
| <i>Urea (mmol/l)</i>                   | 4,8[2,1-9,4]        | 5,7[2,2-18,8]      | 5,7[2,2-18,8]    | 5,65[2,4-17,2]    | <0,001* | 0,596   |
| <i>Sodium (mmol/l)</i>                 | 140,5[131-147]      | 138[30-411]        | 137[30-149]      | 139[127-411]      | <0,001* | 0,006*  |
| <i>Potassium (mmol/l)</i>              | 4,19[3,31-9,16]     | 4,18[3,01-6,06]    | 4,2[3,01-6,06]   | 4,15[3,15-5,8]    | 0,526   | 0,177   |
| <i>Creatinine (µmol/l)</i>             | 82[57-135]          | 94[43-274]         | 94[52-274]       | 95[43-205]        | <0,001* | 0,668   |
| <i>ASAT (U/l)</i>                      | 22[15-55]           | 46,5[16-77]        | 23 [10-86]       | 17,5 [8-422]      | 0,004*  | 0,095   |
| <i>ALAT (U/l)</i>                      | 18,5[10-28]         | 41,5[15-68]        | 24,5 [9-92]      | 22,5[8-261]       | <0,001* | 0,379   |
| <i>Hemoglobin (%)</i>                  | 6[6-9]              | 8[6-10]            | 7,5[5-15]        | 6,5[6-7]          | 0,158   | 0,498   |
| <i>Galectin-3 (ng/ml)</i>              | 9,87[7,26-20,06]    | 14,46[5,28-72,85]  | 13,85[5,28-56,2] | 18,19[10,9-72,85] | <0,001* | <0,001* |
| <i>GPx (U/mgP)</i>                     | 1,94[0,4-5,45]      | 2,13[0,08-14,56]   | 2,03[0,35-5,45]  | 3,14[0,08-14,56]  | 0,018*  | <0,001* |
| <i>MDA (U/mgP)</i>                     | 422,23±169,48       | 2024,38±747,8      | 2184,95±756,58   | 1524,52±437,35    | <0,001* | <0,001* |
| <i>SOD (U/mgP)</i>                     | 0,1±0,003           | 0,0127±0,10±0,0034 | 0,012±0,0034     | 0,011±0,0028      | <0,001* | 0,042*  |
| <b>Drugs</b>                           |                     |                    |                  |                   |         |         |
| <i>antihypertensive medication use</i> | 1(1)                | 145(56,4)          | 104(53,9)        | 41(64,1)          | <0,001* | 0,115   |

|                                    |        |           |           |          |         |         |
|------------------------------------|--------|-----------|-----------|----------|---------|---------|
| <i>antidiabetes medication use</i> | 3(2,9) | 129(50,2) | 115(59,6) | 14(21,9) | <0,001* | <0,001* |
| <i>beta-bloklers</i>               | 0(0)   | 133(51,8) | 106(54,9) | 27(42,2) | -       | 0,077   |
| <i>aldosterone/antagonistes</i>    | 0(0)   | 15(5,8)   | 12(6,2)   | 3(4,7)   | -       | 0,651   |
| <i>diuretics</i>                   | 0(0)   | 61(23,7)  | 47(24,4)  | 14(21,9) | -       | 0,686   |
| <i>antiplatelets</i>               | 0(0)   | 163(63,4) | 118(61,1) | 45(70,3) | -       | 0,187   |
| <i>calcium-antagonist</i>          | 0(0)   | 118(45,9) | 96(49,7)  | 22(34,4) | -       | 0,033*  |
| <i>insulin</i>                     | 0(0)   | 37(14,4)  | 35(18,1)  | 2(3,1)   | -       | 0,003*  |
| <i>ACE inhibitor</i>               | 0(0)   | 164(63,8) | 125(64,8) | 39(60,9) | -       | 0,581   |
| <i>nitrates</i>                    | 0(0)   | 70(27,2)  | 56(29)    | 14(21,9) | -       | 0,257   |
| <i>vitamine k antagonist</i>       | 0(0)   | 201(78,2) | 154(79,8) | 47(73,4) | -       | 0,253   |
| <i>statin</i>                      | 0(0)   | 62(24,1)  | 41(21,2)  | 21(32,8) | -       | 0,064   |
| <i>HBPM</i>                        | 0(0)   | 108(42)   | 76(39,4)  | 32(50)   | -       | 0,144   |

**Table 2:** comparison of demographic and biochemical parameters

|                                   | SG<20 n=96        | SG<20 n=156       | p value |
|-----------------------------------|-------------------|-------------------|---------|
| <i>Gender (male)</i>              | 54(56,3)          | 115(51,3)         | 0,004   |
| <i>Age (year)</i>                 | 61,7±10,33        | 61,51±10,88       | 0,894   |
| <i>BMI (kg/m<sup>2</sup>)</i>     | 28,29±4,83        | 27,8±4,2          | 0,395   |
| <i>history of CAD</i>             | 54(56,3)          | 80(51,3)          | 0,443   |
| <b>Risk factors</b>               |                   |                   |         |
| <i>Hypertension</i>               | 61(63,5)          | 81(51,9)          | 0,071   |
| <i>Diabetes mellitus</i>          | 47(49)            | 85(54,5)          | 0,393   |
| <i>Hyperlipidemic</i>             | 16(16,7)          | 45(28,8)          | 0,028   |
| <i>Obesity</i>                    | 40(41,7)          | 51(32,7)          | 0,15    |
| <i>Smokers</i>                    | 45(46,9)          | 90(57,7)          | 0,112   |
| <i>IDM</i>                        | 14(14,6)          | 40(25,6)          | 0,055   |
| <i>Coronary revascularisation</i> | 8(8,3)            | 24(15,4)          | 0,09    |
| <b>Laboratory data</b>            |                   |                   |         |
| <i>Capillary glycemia</i>         | 7,2[3-35]         | 7,88[2,91-27,67]  | 0,221   |
| <i>LDLc (mmol/l)</i>              | 3,02[0,8-4,67]    | 2,57[0,41-6,26]   | 0,408   |
| <i>HDLc (mmol/l)</i>              | 1,03[0,27-3,84]   | 1,03[0,48-4,27]   | 0,57    |
| <i>TC (mmol/l)</i>                |                   |                   |         |
| <i>TG(mmol/l)</i>                 | 1,61[0,5-5]       | 1,52[0,2-8,8]     | 0,6     |
| <i>Urea</i>                       | 5,8[2,4-17,2]     | 5,6[2,2-18,8]     | 0,344   |
| <i>sodium</i>                     | 137[70-149]       | 138[30-411]       | 0,668   |
| <i>potassium</i>                  | 4,16[3,01-5,41]   | 4,17[3,11-6,06]   | 0,648   |
| <i>creatinine</i>                 | 93,5[43-274]      | 94,5[57-255]      | 0,266   |
| <i>ASAT</i>                       | 26[8-390]         | 27[9-422]         | 0,56    |
| <i>ALAT</i>                       | 22,5[11-132]      | 25[8-261]         | 0,814   |
| <i>Hemoglobin 1ac</i>             | 8[9-14]           | 6[5-15]           | 0,197   |
| <i>Galectin-3(ng/ml)</i>          | 15,39[5,28-56,13] | 13,96[5,99-72,85] | 0,711   |
| <i>GPx (U/mgP)</i>                | 2[0,08-10,52]     | 2,15[0,67-14,56]  | 0,068   |
| <i>MDA (U/mgP)</i>                | 2083,4±843,06     | 2008,02±681,09    | 0,439   |
| <i>SOD (U/mgP)</i>                | 0,0128±0,0037     | 0,012±0,031       | 0,58    |

**Table 3:** multivariate binary logistic regression analysis

|                            | p value | OR    | 95% CI      |
|----------------------------|---------|-------|-------------|
| <i>Gensini score</i>       | 0,012*  | 1,007 | 1,001-1,012 |
| <i>Diabetes - mellitus</i> | <0,001* | 0,171 | 0,08-0,367  |
| <i>hypertension</i>        | 0,038*  | 2,257 | 1,046-4,871 |
| <i>dyslipidemia</i>        | 0,139   | 1,846 | 0,819-4,16  |
| <i>obesity</i>             | 0,412   | 0,73  | 0,343-1,55  |
| <i>CAD history</i>         | 0,134   | 0,599 | 0,306-1,172 |
| <i>smoking</i>             | 0,044   | 0,428 | 0,187-0,977 |

**Table 4:** Correlation of systemic galectin-3 levels with risk factors in CAD patients

| Correlation of galectin-3 with | Pearson correlation | P value |
|--------------------------------|---------------------|---------|
| <i>HDLc (mmol/l)</i>           | -0,117              | 0,01    |
| <i>Triglyceride(mmol/l)</i>    | 0,226               | 0,001   |
| <i>Urea</i>                    | 0,171               | 0,008   |
| <i>creatinine</i>              | 0,253               | <0,001  |
| <i>Homocysteie (µM)</i>        | 0,243               | 0,001   |
| <i>GPx (U/mgP)</i>             | 0,218               | 0,001   |
| <i>MDA(U/mgP)</i>              | -0,203              | 0,002   |

### 5.3. Diagnostic value of galectin-3 for CAD

ROC curves were plotted according to the data of CHD patient and control patients; galectin-3 had the greatest area under the curve (AUC) of 0,801 ( $P < 0.001$ ), with an optimal cutoff of 11,73ng/ml, wielding a sensitivity of 72,6% and a specificity of 82,3% (Figure 1C).

During 12 month follow-up period, 12 patients died 13 were restenosed and 45 were re-hospitalized due to worsened CHD.

### 5.4. Stress oxidative parameters

The parameters that show oxidant and antioxidant status are presented in table 1. As observed, the CHD patients exhibited elevated states of oxidative stress (indicated by both the GPx concentration and the level of MDA) when compared to the control population. In contrast, the activity of erythrocyte SOD in CHD patients was lower when compared to the control population. According to the stability of CAD, we subdivided the CHD population into 2 groups (stable CAD and unstable CAD): The levels of erythrocyte-derived SOD and GPx as well as MDA, a lipid oxidation marker in CHD patients had significantly different when compared CHD patients vs controls and CAD stable vs CAD unstable patients. Among patients with unstable CAD, the variation of stress parameters after 48 hours showed that were a significant difference in MDA levels ( $p=0.008$ ) and SOD levels SOD levels (0.041) but no variation in GPx levels. By contrast, we did not find any difference in the level of many oxidative stress status parameters according to the stenosis degree or according to our number of vessel stenosis between any of four CAD groups. There was also no difference in CHD patient populations that were subdivided into four groups (0: stenosis less than 50%, 1: stenosis of one vessel, 2: stenosis of two vessels and 3: stenosis of three vessels) (data not shown). There was also no difference between the groups with high and low Gensini scores (tableII).

### 5.5. Coronary angiography and assessment of coronary atherosclerosis severity

Gensini scores were available in all patients. Comparison of demographic, clinical and laboratory characteristics of the subjects according to Gensini score is expressed in table 2. Hyperlipidemic patients were higher in the group with a higher Gensini score ( $p=0.028$ ). There were no differences in terms of presence of diabetes, hypertension and smokers of CAD between the groups with high and low Gensini scores. We did not find any difference in the level of stress status parameter according to the stenosis degree, between the groups with high and low Gensini scores (Table 2).

In the multivariate binary logistic regression analysis, Gensini score was significant independent predictor for CAD. Diabetes mellitus and hypertensive were other significant predictors for CAD in subjects with CHD (Table 3).

According to multivariate logistic regression analysis with previous coronary risk factors, such as Gensini score, diabetes mellitus, <http://www.acmcasereport.com/>

HTA and smoking, all of these were independently associated with severity of CAD (Table 3).

## 6. Discussion

Multiple processes of inflammation influence the initiation, progression and propagation of atherosclerosis in coronary arterial disease. Previous studies that Gal-3 has been shown to be an important contributor to inflammation and markers of systemic inflammation through macrophages activation promotion and monocytes attraction predicts CVD (De Boer RA, 2010; Karlsson A, 2009; Falcome C, 2011; Kuwabara I, 1996). Analysis of group of symptomatic subjects with CAD showed that Gal-3 levels were higher in patients with unstable angina as compared to stable angina. This suggested the involvement of Gal-3 in promoting macrophages activation and monocytes attraction (Henderson, 2009). This finding indicate that Gal-3 play an important role in many phase of acute and chronic inflammatory response.

In a study by Nachtigal et al.1998, Gal-3 levels were found to be higher in atherosclerotic arteries than umbilical cord arteries. Additionally, in the absence of galectin-3 expression, the incidence of atheromatous plaques was lower and galectin-3 was strongly expressed in the foam cells of the atheromatous plaques (Nachtigal et al, 2008). All of these observations suggest that Gal-3 may involve in the active phase of the vulnerable atherosclerotic plaques. We found elevated galectin-3 levels in patients with unstable CAD as compared to control group (figure 1D).

Additionally, we found that galectine-3 is higher in patients with CHD as compared to control and unstable CAD group. These patients with CHD had higher baseline Gal-3 concentration (median 14.46 ng/ml [5.28-72.85] compared the controls and the optimal cut-off for prediction of CAD was 11,737 ng/ml. Many observations have indicated that Gal-3 measured in the acute phase of myocardial infarctus was higher and that the cut-off value was 18,1ng/ml [Iwona S k and al, 2013]. The patients with three-vessel disease tended to have higher levels of Gal-3, by contrast, we did not find any difference in the level of Gal-3 according to our number of vessel stenosis between any of four CAD groups.

Tunón et al. evaluated the prognostic value of plasma biomarkers in patients with chronic coronary artery disease. They showed that development of mortality wase independently associated with increased levels of galectin-3. De Boer et al. evaluated the relationship between galectin-3 and survival in the general population (de Boer RA, 2012).

Compared with previous study in the literature, we founded lower Gal-3 levels in unstable patients in our cohort. In a study by Falcone et al., galectin-3 levels were 27.75 ng/mL in unstable patients (Falcone et al,2011).

In our study, during 12 month follow-up period, 12 (4.7%) patients died, 13 (5.1%) were restenosed and 45 (17.5%) were re-hospitalized due to worsened CHD.

The association between Gensini scores and galectin-3 suggested that galectin-3 may predict the severity of the coronary artery disease in clinical practice, and may become an additional tool in identifying high-risk patients. The median Gensini score of the patients was 20, and according to this value, patients were separated in two groups: less intensive CAD and intensive CAD. There was no significant difference with regard about the gensini score.

Inflammation and oxidative stress play a key role in all stages of atherosclerosis and vascular remodeling, from initiation, progression of athermanous plaques and luminal narrowing, finally leading to acute coronary syndromes as a consequence of plaque rupture (Yip HK, 2005). In addition, we found that Gal-3 was positively correlated with GPx activity but had a negative correlation with MDA levels. We have not found any relation between oxidative stress markers and the complexity of CAD, determined according to Gensini score.

## 7. Conclusion

Our study indicates that Gal-3 measured in CAD and unstable CAD could provide additional information about the pathobiology and prognosis in this group of patients, but further studies are needed. According to our findings, galectin-3 may become a major biomarker and provide complementary information for assessment of early risk stratification in patients with ACS.

## 8. Acknowledgments

A limitation of our study could be the sample size. It is associated with the fact that only part of the subjects met inclusion and exclusion criteria. Higher Gensini scores usually tend to accompany with high-risk patients, but our study sample was too small to adjust the potential confounders with a regression model.

## References

- Ahsan H, Ali A, Ali R. Oxygen Free Radicals and Systemic Autoimmunity. *Clinical and Experimental Immunology*. 2003; 131(3): 398–404.
- Charalambos A, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G, et al. Effects of Antioxidant Vitamins C and E on Endothelial Function and Thrombosis/fibrinolysis System in Smokers. *Thrombosis and Haemostasis*. 2003; 89(6): 990-95.
- Beyer WF, Fridovich I. Assaying for Superoxide Dismutase Activity: Some Large Consequences of Minor Changes in Conditions. *Analytical Biochemistry*. 1987; 161(2): 559-66.
- de Boer, Rudolf A, Lok DJA, Jaarsma T, Meer PVD, Voors AA, et al. Predictive Value of Plasma Galectin-3 Levels in Heart Failure with Reduced and Preserved Ejection Fraction. *Annals of Medicine*. 2011; 43(1): 60-8.
- de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, vanGilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. *J Intern Med*. 2012; 272(1): 55-64.
- Rio D, Daniele, Stewart AJ, Pellegrini N. A Review of Recent Studies on Malondialdehyde as Toxic Molecule and Biological Marker of Oxidative Stress. *Nutrition, Metabolism, and Cardiovascular Diseases: NMCD*. 2005; 15(4): 316-28.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2003; 26: S5-20.
- Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. Galectin-3 Plasma Levels and Coronary Artery Disease: A New Possible Biomarker of Acute Coronary Syndrome. *International Journal of Immunopathology and Pharmacology*. 2011; 24 (4): 905–13.
- Felker G, Fiuzat MM, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in Ambulatory Patients with Heart Failure: Results from the HF-ACTION Study. *Circulation. Heart Failure*. 2012; 5 (1): 72-8.
- Flohé L, Günzler WA. Assays of Glutathione Peroxidase. *Methods in Enzymology*. 1984; 105: 114-21.
- Elena G, Ley K. Immune and Inflammatory Mechanisms of Atherosclerosis (\*). *Annual Review of Immunology*. 2009; 27: 165–97.
- Gensini GG. A More Meaningful Scoring System for Determining the Severity of Coronary Heart Disease. *The American Journal of Cardiology*. 1983; 51(3): 606.
- Wilson GE, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Morrow. Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. *Clinical Chemistry*. 2012; 58(1): 267-73.
- Göran KH. Inflammation, Atherosclerosis, and Coronary Artery Disease. *The New England Journal of Medicine*. 2005; 352(16): 1685-95.
- Göran KH, Robertson AKL, Söderberg-Nauclér C. Inflammation and Atherosclerosis. *Annual Review of Pathology*. 2006; 1: 297–329.
- Neil CH, Sethi T. The Regulation of Inflammation by Galectin-3. *Immunological Reviews*. 2009; 230: 160-71.
- Hughes RC. The Galectin Family of Mammalian Carbohydrate-Binding Molecules. *Biochemical Society Transactions*. 1997; 25(4): 1194-98.
- Karlsson A, Christenson K, Matlak M, et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. *Glycobiology*. 2009; 19(1): 16–20.
- Shogo K, Kaji T. Atherosclerosis and Extracellular Matrix. *Journal of Atherosclerosis and Thrombosis*. 2003; 10(5): 267-74.
- Heechul K, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and Immunohistochemical Localization of Galectin-3 in Various Mouse Tissues. *Cell Biology International*. 2007; 31(7): 655-62.
- Kuwabara I, Liu FT. Galectin-3 promotes adhesion of human neutrophil to laminin. *J Immunol*. 1996; 156: 3939–44.
- Tao-Hua L, Huang XQ, Tan HM. Vascular Fibrosis in Atherosclerosis.” *Cardiovascular Pathology: The Official Journal of the Society for Cardiovascular Pathology*. 2013; 22(5): 401–7.
- Yen-Hung L, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, et al. The Relationship between Serum Galectin-3 and Serum Markers

- of Cardiac Extracellular Matrix Turnover in Heart Failure Patients. *Clinica Chimica Acta; International Journal of Clinical Chemistry*. 2009; 409(1-2): 96-9.
24. Michiels C, Raes M, Toussaint O, Remacle J. Importance of Se-Glutathione Peroxidase, Catalase, and Cu/Zn-SOD for Cell Survival against Oxidative Stress. *Free Radical Biology & Medicine*. 1994; 17(3): 235-48.
  25. Kathryn JM, Tabas I. Macrophages in the Pathogenesis of Atherosclerosis. *Cell*. 2011; 145(3): 341-55.
  26. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3 expression in human atherosclerotic lesions. *Am J Pathol*. 1998; 152(5): 1199-208.
  27. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. *Am J Pathol*. 2008; 172(1): 247-55.
  28. Yoshimichi O. Oxidative Stress in Allergic and Inflammatory Skin Diseases." *Current Drug Targets. Inflammation and Allergy*. 2005; 4(4): 517-19.
  29. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, et al. Guidelines for Percutaneous Transluminal Coronary Angioplasty. A Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). *Circulation*. 1988; 78(2): 486-502.
  30. Roland S, Keaney JF. Role of Oxidative Modifications in Atherosclerosis. *Physiological Reviews*. 2004; 84(4): 1381-478.
  31. Iwona S, Wlazel RN, Migala M, Bajon-Laskowska K, Szadkowska K, Zielińska M, et al. The Association between Galectin-3 and Occurrence of Reinfarction Early after First Myocardial Infarction Treated Invasively. *Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals*. 2013; 18(8): 655-59.
  32. Tunón J, Blanco-Colio L, Cristóbal C, Tarín N, Higuera J, Huelmos A, et al. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal pro-brain natriuretic peptide to predict cardio-vascular events in patients with coronary artery disease. *Am J Cardiol*. 2014; 113(3): 434-40.
  33. Johanna W, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes. *The Journal of Clinical Endocrinology and Metabolism*. 2010; 95(3): 1404-11.
  34. Ri-Yao Y, Rabinovich GA, Liu FT. Galectins: Structure, Function and Therapeutic Potential. *Expert Reviews in Molecular Medicine*. 2008; 10: e17.
  35. Hon-Kan Y, Hung WC, Yang CH, Chen YH, Cheng CI, Chen SM, et al. Serum Concentrations of High-Sensitivity C-Reactive Protein Predict Progressively Obstructive Lesions rather than Late Restenosis in Patients with Unstable Angina Undergoing Coronary Artery Stenting. *Circulation Journal: Official Journal of the Japanese Circulation Society*. 2005; 69(10): 1202-7.
  36. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid Peroxidation in Maternal and Cord Blood and Protective Mechanism against Activated-Oxygen Toxicity in the Blood. *American Journal of Obstetrics and Gynecology*. 1979; 135(3): 372-76.